Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + dalpiciclib + endocrine therapy for HR-positive/HER2-positive advanced breast cancer
ChiCTR2400083548Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Jinzhou Medical University
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and dalpiciclib in breast cancer, sponsored by The First Affiliated Hospital of Jinzhou Medical University. Primary endpoint: Objective response rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400083548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083548.